Bio-Path Holdings to Announce First Quarter 2024 Financial Results on May 15, 2024
Bio-Path Holdings to Announce First Quarter 2024 Financial Results on May 15, 2024
HOUSTON, May 08, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Wednesday, May 15, 2024 at 8:30 a.m. ET to report financial results for the first quarter ended March 31, 2024 and to provide a business overview.
休斯頓，2024 年 5 月 8 日（GLOBE NEWSWIRE）—— Bio-Path Holdings, Inc.，（納斯達克股票代碼：BPTH）是一家利用其專有的 DNaBilize 的生物技術公司 開發靶向核酸癌藥物組合的反義RNAi納米粒子技術今天宣佈，它將在美國東部時間2024年5月15日星期三上午8點30分舉辦電話會議和網絡音頻直播，以報告截至2024年3月31日的第一季度財務業績並提供業務概覽。
To access the live conference call, please call (844) 481-3014 (domestic) or (412) 317-1879 (international) at least five minutes prior to the start time. A live audio webcast of the call will also be available on the Presentations section of the Company's website, . An archived webcast will be available on the Bio-Path website approximately two hours after the event.
要參加實時電話會議，請在開始時間前至少五分鐘致電（844）481-3014（國內）或（412）317-1879（國際）。本次電話會議的網絡直播也將在公司網站的 “演示” 部分播出。活動結束大約兩小時後，將在Bio-Path網站上提供存檔的網絡直播。
About Bio-Path Holdings, Inc.
關於 Bio-Path 控股公司
Bio-Path is a biotechnology company developing DNAbilize, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion. Bio-Path's lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase 2 study for blood cancers, and BP1001-A, a drug product modification of prexigebersen, is in a Phase 1/1b study for solid tumors. The Company's second product, BP1002, which targets the Bcl-2 protein, is being evaluated for the treatment of blood cancers and solid tumors, including lymphoma and acute myeloid leukemia. In addition, an IND is expected to be filed for BP1003, a novel liposome-incorporated STAT3 antisense oligodeoxynucleotide developed by Bio-Path as a specific inhibitor of STAT3.
Bio-Path是一家生物技術公司，正在開發DNaBilize，這是一項新技術，已經生產出了一系列可以通過簡單的靜脈輸液給藥的RNAi納米顆粒藥物。Bio-Path的主要候選產品prexigebersen（BP1001，靶向Grb2蛋白）正在進行鍼對血液癌的2期研究，而prexigebersen的藥物產品改性 BP1001-A 正在進行鍼對實體瘤的1/1b期研究。該公司的第二款靶向Bcl-2蛋白的產品 BP1002 正在接受評估，用於治療血液癌和實體瘤，包括淋巴瘤和急性髓系白血病。此外，預計將申請 BP1003 的臨床試驗申請，這是一種由Bio-Path開發的含脂質體的新型 STAT3 反義寡脫氧核苷酸，作爲 STAT3 的特異抑制劑開發。
For more information, please visit the Company's website at
欲了解更多信息，請訪問公司的網站
Contact Information:
Investors
聯繫信息：
投資者
Will O'Connor
Stern Investor Relations
212-362-1200
will@sternir.com
威爾·奧康納
斯特恩投資者關係
212-362-1200
will@sternir.com
Doug Morris
Investor Relations
Bio-Path Holdings, Inc.
832-742-1369
道格·莫里斯
投資者關係
Bio-Path 控股有限公司
832-742-1369